Skip to main content
Erschienen in: Endocrine 1/2018

07.02.2018 | Clinical Management of Endocrine Diseases

Practical issues for the management of hyponatremia in oncology

Erschienen in: Endocrine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Hyponatremia is common in cancer patients and has a negative impact on outcomes and survival. Both the diagnosis and treatment of hyponatremia are challenging. Easy-to-use, practical guidelines are needed. The aim of this article is to discuss practical issues related to the diagnostic workup and management of hyponatremia, with particular attention to complex patients, such as those affected by neoplastic diseases. Admittedly, these patients may present several comorbidities, which may cause sodium alterations. In addition, multidrug therapy may precipitate serum sodium fall. An algorithm for the diagnosis and treatment of hyponatremia was also developed, based on the discussion of the results of a questionnaire completed by the authors and of the published recommendations/guidelines on hyponatremia. The goal was to produce an algorithm that was as simple as possible but still comprehensive, without compromising information completeness. Many explanatory notes were added with the aim of guiding clinicians throughout the management of complex patients with hyponatremia, such as those with cancer. The resulting algorithm and supporting literature are presented.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat F.A. Schutz, W. Xie, F. Donskov, M. Sircar, D.F. McDermott, B.I. Rini, N. Agarwal, S.K. Pal, S. Srinivas, C. Kollmannsberger, S.A. North, L.A. Wood, U. Vaishampayan, M.H. Tan, M.J. Mackenzie, J.L. Lee, S.Y. Rha, T. Yuasa, D.Y. Heng, T.K. Choueiri, The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur. Urol. 65(4), 723–730 (2014)CrossRefPubMed F.A. Schutz, W. Xie, F. Donskov, M. Sircar, D.F. McDermott, B.I. Rini, N. Agarwal, S.K. Pal, S. Srinivas, C. Kollmannsberger, S.A. North, L.A. Wood, U. Vaishampayan, M.H. Tan, M.J. Mackenzie, J.L. Lee, S.Y. Rha, T. Yuasa, D.Y. Heng, T.K. Choueiri, The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur. Urol. 65(4), 723–730 (2014)CrossRefPubMed
3.
Zurück zum Zitat H. Raftopoulos, Diagnosis and management of hyponatremia in cancer patients. Support. Care Cancer 15(12), 1341–1347 (2007)CrossRefPubMed H. Raftopoulos, Diagnosis and management of hyponatremia in cancer patients. Support. Care Cancer 15(12), 1341–1347 (2007)CrossRefPubMed
4.
Zurück zum Zitat G. Liamis, H. Milionis, M. Elisaf, A review of drug-induced hyponatremia. Am. J. Kidney Dis. 52(1), 144–153 (2008)CrossRefPubMed G. Liamis, H. Milionis, M. Elisaf, A review of drug-induced hyponatremia. Am. J. Kidney Dis. 52(1), 144–153 (2008)CrossRefPubMed
5.
Zurück zum Zitat T. Berghmans, M. Paesmans, J.J. Body, A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support. Care Cancer 8(3), 192–197 (2000)CrossRefPubMed T. Berghmans, M. Paesmans, J.J. Body, A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support. Care Cancer 8(3), 192–197 (2000)CrossRefPubMed
7.
Zurück zum Zitat O. Hansen, P. Sorensen, K.H. Hansen, The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 68(1), 111–114 (2010)CrossRefPubMed O. Hansen, P. Sorensen, K.H. Hansen, The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 68(1), 111–114 (2010)CrossRefPubMed
8.
Zurück zum Zitat A.N. Jeppesen, H.K. Jensen, F. Donskov, N. Marcussen, H. von der Maase, Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br. J. Cancer 102(5), 867–872 (2010)CrossRefPubMedPubMedCentral A.N. Jeppesen, H.K. Jensen, F. Donskov, N. Marcussen, H. von der Maase, Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br. J. Cancer 102(5), 867–872 (2010)CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat S.M. Doshi, P. Shah, X. Lei, A. Lahoti, A.K. Salahudeen, Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am. J. Kidney Dis. 59(2), 222–228 (2012)CrossRefPubMed S.M. Doshi, P. Shah, X. Lei, A. Lahoti, A.K. Salahudeen, Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am. J. Kidney Dis. 59(2), 222–228 (2012)CrossRefPubMed
10.
Zurück zum Zitat A. Sengupta, S.N. Banerjee, N.M. Biswas, D. Jash, K. Saha, A. Maji, A. Bandyopadhyaya, S. Agarwal, The incidence of hyponatraemia and its effect on the ECOG performance status among lung cancer patients. J. Clin. Diagn. Res 7(8), 1678–1682 (2013)PubMedPubMedCentral A. Sengupta, S.N. Banerjee, N.M. Biswas, D. Jash, K. Saha, A. Maji, A. Bandyopadhyaya, S. Agarwal, The incidence of hyponatraemia and its effect on the ECOG performance status among lung cancer patients. J. Clin. Diagn. Res 7(8), 1678–1682 (2013)PubMedPubMedCentral
11.
Zurück zum Zitat R. Berardi, M. Caramanti, M. Castagnani, S. Guglielmi, F. Marcucci, A. Savini, F. Morgese, S. Rinaldi, C. Ferrini, M. Tiberi, M. Torniai, F. Rovinelli, I. Fiordoliva, A. Onofri, S. Cascinu, Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support. Care Cancer 23(10), 3095–3101 (2015)CrossRefPubMed R. Berardi, M. Caramanti, M. Castagnani, S. Guglielmi, F. Marcucci, A. Savini, F. Morgese, S. Rinaldi, C. Ferrini, M. Tiberi, M. Torniai, F. Rovinelli, I. Fiordoliva, A. Onofri, S. Cascinu, Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support. Care Cancer 23(10), 3095–3101 (2015)CrossRefPubMed
12.
Zurück zum Zitat J.G. Verbalis, S.R. Goldsmith, A. Greenberg, C. Korzelius, R.W. Schrier, R.H. Sterns, C.J. Thompson, Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am. J. Med. 126(10 Suppl 1), S1–S42 (2013)CrossRefPubMed J.G. Verbalis, S.R. Goldsmith, A. Greenberg, C. Korzelius, R.W. Schrier, R.H. Sterns, C.J. Thompson, Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am. J. Med. 126(10 Suppl 1), S1–S42 (2013)CrossRefPubMed
13.
Zurück zum Zitat G. Spasovski, R. Vanholder, B. Allolio, D. Annane, S. Ball, D. Bichet, G. Decaux, W. Fenske, E.J. Hoorn, C. Ichai, M. Joannidis, A. Soupart, R. Zietse, M. Haller, S. van der Veer, W. Van Biesen, E. Nagler; Hyponatraemia Guideline Development Group, Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol. Dial. Transplant. 29(Suppl 2), i1–i39 (2014)CrossRefPubMed G. Spasovski, R. Vanholder, B. Allolio, D. Annane, S. Ball, D. Bichet, G. Decaux, W. Fenske, E.J. Hoorn, C. Ichai, M. Joannidis, A. Soupart, R. Zietse, M. Haller, S. van der Veer, W. Van Biesen, E. Nagler; Hyponatraemia Guideline Development Group, Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol. Dial. Transplant. 29(Suppl 2), i1–i39 (2014)CrossRefPubMed
15.
Zurück zum Zitat P. Grant, J. Ayuk, P.M. Bouloux, M. Cohen, I. Cranston, R.D. Murray, A. Rees, N. Thatcher, A. Grossman, The diagnosis and management of inpatient hyponatraemia and SIADH. Eur. J. Clin. Invest. 45(8), 888–894 (2015)CrossRefPubMedPubMedCentral P. Grant, J. Ayuk, P.M. Bouloux, M. Cohen, I. Cranston, R.D. Murray, A. Rees, N. Thatcher, A. Grossman, The diagnosis and management of inpatient hyponatraemia and SIADH. Eur. J. Clin. Invest. 45(8), 888–894 (2015)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat C. Grohé, R. Berardi, V. Burst, Hyponatraemia–SIADH in lung cancer diagnostic and treatment algorithms. Crit. Rev. Oncol. Hematol. 96(1), 1–8 (2015)CrossRefPubMed C. Grohé, R. Berardi, V. Burst, Hyponatraemia–SIADH in lung cancer diagnostic and treatment algorithms. Crit. Rev. Oncol. Hematol. 96(1), 1–8 (2015)CrossRefPubMed
17.
Zurück zum Zitat R. De las Penas, Y. Escobar, F. Henao, A. Blasco, C.A. Rodriguez; Spanish Society for Medical, O., SEOM guidelines on hydroelectrolytic disorders. Clin. Transl. Oncol. 16(12), 1051–1059 (2014)CrossRef R. De las Penas, Y. Escobar, F. Henao, A. Blasco, C.A. Rodriguez; Spanish Society for Medical, O., SEOM guidelines on hydroelectrolytic disorders. Clin. Transl. Oncol. 16(12), 1051–1059 (2014)CrossRef
18.
Zurück zum Zitat D.H. Ellison, T. Berl, Clinical practice. The syndrome of inappropriate antidiuresis. N. Engl. J. Med. 356(20), 2064–2072 (2007)CrossRefPubMed D.H. Ellison, T. Berl, Clinical practice. The syndrome of inappropriate antidiuresis. N. Engl. J. Med. 356(20), 2064–2072 (2007)CrossRefPubMed
19.
Zurück zum Zitat B.O. Saeed, D. Beaumont, G.H. Handley, J.U. Weaver, Severe hyponatraemia: investigation and management in a district general hospital. J. Clin. Pathol. 55(12), 893–896 (2002)CrossRefPubMedPubMedCentral B.O. Saeed, D. Beaumont, G.H. Handley, J.U. Weaver, Severe hyponatraemia: investigation and management in a district general hospital. J. Clin. Pathol. 55(12), 893–896 (2002)CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat C.M. Nzerue, H. Baffoe-Bonnie, W. You, B. Falana, S. Dai, Predictors of outcome in hospitalized patients with severe hyponatremia. J. Natl Med. Assoc. 95(5), 335–343 (2003)PubMedPubMedCentral C.M. Nzerue, H. Baffoe-Bonnie, W. You, B. Falana, S. Dai, Predictors of outcome in hospitalized patients with severe hyponatremia. J. Natl Med. Assoc. 95(5), 335–343 (2003)PubMedPubMedCentral
21.
Zurück zum Zitat H.J. Adrogué, Consequences of inadequate management of hyponatremia. Am. J. Nephrol. 25(3), 240–249 (2005)CrossRefPubMed H.J. Adrogué, Consequences of inadequate management of hyponatremia. Am. J. Nephrol. 25(3), 240–249 (2005)CrossRefPubMed
22.
Zurück zum Zitat R.H. Sterns, Disorders of plasma sodium–causes, consequences, and correction. N. Engl. J. Med. 372(1), 55–65 (2015)CrossRefPubMed R.H. Sterns, Disorders of plasma sodium–causes, consequences, and correction. N. Engl. J. Med. 372(1), 55–65 (2015)CrossRefPubMed
23.
Zurück zum Zitat B.F. Palmer, Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol. Metab. 14(4), 182–187 (2003)CrossRefPubMed B.F. Palmer, Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol. Metab. 14(4), 182–187 (2003)CrossRefPubMed
24.
Zurück zum Zitat S.S. Waikar, D.B. Mount, G.C. Curhan, Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am. J. Med. 122(9), 857–865 (2009)CrossRefPubMedPubMedCentral S.S. Waikar, D.B. Mount, G.C. Curhan, Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am. J. Med. 122(9), 857–865 (2009)CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat G. Corona, C. Giuliani, J.G. Verbalis, G. Forti, M. Maggi, A. Peri, Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One 10(4), e0124105 (2015)CrossRefPubMedPubMedCentral G. Corona, C. Giuliani, J.G. Verbalis, G. Forti, M. Maggi, A. Peri, Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One 10(4), e0124105 (2015)CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, J.J. Grantham, E. Higashihara, R.D. Perrone, H.B. Krasa, J. Ouyang, F.S. Czerwiec, Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367(25), 2407–2418 (2012)CrossRefPubMedPubMedCentral V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, J.J. Grantham, E. Higashihara, R.D. Perrone, H.B. Krasa, J. Ouyang, F.S. Czerwiec, Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367(25), 2407–2418 (2012)CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat C. Petereit, O. Zaba, I. Teber, H. Luders, C. Grohe, A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm. Med. 13, 55 (2013)CrossRefPubMedPubMedCentral C. Petereit, O. Zaba, I. Teber, H. Luders, C. Grohe, A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm. Med. 13, 55 (2013)CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat A.K. Salahudeen, N. Ali, M. George, A. Lahoti, S. Palla, Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer 120(5), 744–751 (2014)CrossRefPubMed A.K. Salahudeen, N. Ali, M. George, A. Lahoti, S. Palla, Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer 120(5), 744–751 (2014)CrossRefPubMed
30.
Zurück zum Zitat R. Berardi, S. Rinaldi, M. Caramanti, C. Grohe, M. Santoni, F. Morgese, M. Torniai, A. Savini, I. Fiordoliva, S. Cascinu, Hyponatremia in cancer patients: Time for a new approach. Crit. Rev. Oncol. Hematol. 102, 15–25 (2016)CrossRefPubMed R. Berardi, S. Rinaldi, M. Caramanti, C. Grohe, M. Santoni, F. Morgese, M. Torniai, A. Savini, I. Fiordoliva, S. Cascinu, Hyponatremia in cancer patients: Time for a new approach. Crit. Rev. Oncol. Hematol. 102, 15–25 (2016)CrossRefPubMed
31.
Zurück zum Zitat B. Thajudeen, A.K. Salahudeen, Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives. Cancer Manag. Res. 8, 105–114 (2016)CrossRefPubMedPubMedCentral B. Thajudeen, A.K. Salahudeen, Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives. Cancer Manag. Res. 8, 105–114 (2016)CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat R.J. Gralla, F. Ahmad, J.D. Blais, J. Chiodo 3rd, W. Zhou, L.A. Glaser, F.S. Czerwiec, Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Cancer Med 6(4), 723–729 (2017)CrossRefPubMedPubMedCentral R.J. Gralla, F. Ahmad, J.D. Blais, J. Chiodo 3rd, W. Zhou, L.A. Glaser, F.S. Czerwiec, Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Cancer Med 6(4), 723–729 (2017)CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat M.H. Warner, S. Holding, ES. Kilpatrick, The effect of newly diagnosed hypothyroidism on serum sodiumconcentrations: a retrospective study. Clin Endocrinol. 64(5), 598–599 (2006)CrossRef M.H. Warner, S. Holding, ES. Kilpatrick, The effect of newly diagnosed hypothyroidism on serum sodiumconcentrations: a retrospective study. Clin Endocrinol. 64(5), 598–599 (2006)CrossRef
Metadaten
Titel
Practical issues for the management of hyponatremia in oncology
Publikationsdatum
07.02.2018
Erschienen in
Endocrine / Ausgabe 1/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1547-y

Weitere Artikel der Ausgabe 1/2018

Endocrine 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.